Fresolimumab, a neutralizing antibody that targets TGF-β1,2,3, has confirmed its anti-tumor feasibility and safety in a phase II clinical trial (NCT01401062), in which researchers focused on the cooperation of Fresolimumab and focal irradiation while applying to 23 patients with metastatic BC. Here, TGFB1 is linked to neoplasm.